RT Journal Article
SR Electronic
T1 Longitudinal laboratory testing tied to PCR diagnostics in COVID-19 patients reveals temporal evolution of distinctive coagulopathy signatures
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.05.21.20109439
DO 10.1101/2020.05.21.20109439
A1 Pawlowski, Colin
A1 Wagner, Tyler
A1 Puranik, Arjun
A1 Murugadoss, Karthik
A1 Loscalzo, Liam
A1 Venkatakrishnan, AJ
A1 Pruthi, Rajiv K.
A1 Houghton, Damon E.
A1 O’Horo, John C.
A1 Morice, William G.
A1 Halamka, John
A1 Badley, Andrew D.
A1 Barnathan, Elliot S.
A1 Makimura, Hideo
A1 Khan, Najat
A1 Soundararajan, Venky
YR 2020
UL http://medrxiv.org/content/early/2020/05/23/2020.05.21.20109439.abstract
AB Temporal inference from laboratory testing results and their triangulation with clinical outcomes as described in the associated unstructured text from the providers’ notes in the Electronic Health Record (EHR) is integral to advancing precision medicine. Here, we studied 181 COVIDpos and 7,775 COVIDneg patients subjected to 1.3 million laboratory tests across 194 assays during a two-month observation period centered around their SARS-CoV-2 PCR testing dates. We found that compared to COVIDneg at the time of clinical presentation and diagnostic testing, COVIDpos patients tended to have higher plasma fibrinogen levels and similarly low platelet counts, with approximately 25% of patients in both cohorts showing outright thrombocytopenia. However, these measures show opposite longitudinal trends as the infection evolves, with declining fibrinogen and increasing platelet counts to levels that are lower and higher compared to the COVIDneg cohort, respectively. Our EHR augmented curation efforts suggest a minority of patients develop thromboembolic events after the PCR testing date, including rare cases with disseminated intravascular coagulopathy (DIC), with most patients lacking the platelet reductions typically observed in consumptive coagulopathies. These temporal trends present, for the first time, fine-grained resolution of COVID-19 associated coagulopathy (CAC), via a digital framework that synthesizes longitudinal lab measurements with structured medication data and neural network-powered extraction of outcomes from the unstructured EHR. This study demonstrates how a precision medicine platform can help contextualize each patient’s specific coagulation profile over time, towards the goal of informing better personalization of thromboprophylaxis regimen.Competing Interest StatementSome authors are employees of nference and the Janssen pharmaceutical companies of Johnson & Johnson (J&J), with financial interests in these companies.Funding StatementNo external funding was receivedAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This research was conducted under IRB 20-003278 approved by the Mayo Clinic, titled 'Study of COVID-19 patient characteristics with augmented curation of Electronic Health Records (EHR) to inform strategic and operational decisions'. All analysis of EHRs was performed in the privacy-preserving environment secured and controlled by the Mayo Clinic. Nference, the Mayo Clinic, and the Janssen pharmaceutical companies of Johnson & Johnson (J&J) subscribe to the basic ethical principles underlying the conduct of research involving human subjects as set forth in the Belmont Report and strictly ensure compliance with the Common Rule in the Code of Federal Regulations (45 CFR 46) on the Protection of Human Subjects.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data necessary are self-contained in the manuscript